Decreasing the Search Timeframe and Improving ...

Abstracts / Biol Blood Marrow Transplant 22 (2016) S19eS481

p¼0.04) (Figure 2), including after adjustment for donor type and HLA disparity. Although the incidence of grade II to IV aGVHD was similar in both groups (73% vs.83%, p¼0.31), grade III to IV aGVHD was lower in the eosinophilia group (13% vs 32%, p¼0.07). In terms of target organs, the incidence of skin and liver aGVHD were similar between both groups (86.7 % vs 78.0 %, p¼0.40 for skin aGVHD; 4.4 % vs 14.6%, p¼0.14 for liver aGVHD). However, that of gut aGVHD was lower in the eosinophilia group (37.8 % vs 60.9 %, p¼0.05). In the non-aGVHD group, there was no significant difference in the 3-year overall survival and non-relapse mortality between both the eosinophilia group and the noneosinophilia group (77.6 % vs 60.8, p¼0.17; 19.3 % vs 28.4 %, p¼0.45). Conclusion: We found several associations between eosinophilia and aGVHD, which is consistent with previous studies. Among the aGVHD group, the 3-year nonrelapse mortality was significantly lower in patients who experienced eosinophilia, and they were unlikely to develop grade III to IV aGVHD, especially gut aGVHD. Our results suggest that peripheral eosinophilia in patients with aGVHD may prevent severe aGVHD progression after allo-HSCT.

S355

530 Decreasing the Search Timeframe and Improving Transplant Center Satisfaction for Patients Receiving an Unrelated Allogeneic Hematopoietic Stem Cell Transplant Erin Schubert1, Kimberly Wadsworth 2, Abby McDonald 2, Christina Bade1, Abby Martfeld2, Melissa Roux1, Leah Schroer2, Kathryn Hansen3, Katie A. Howe 2, Kristin Naruko1. 1 Case Management Operations, National Marrow Donor Program, Minneapolis, MN; 2 Immunogenetic Operations and Research, National Marrow Donor Program, Minneapolis, MN; 3 Transplant Services, National Marrow Donor Program, Minneapolis, MN Patients that move quickly to transplant tend to have better post-transplant outcomes. Looking for a matched unrelated donor is typically the longest step for a patient receiving an unrelated allogeneic transplant. As part of a pilot project, 20 diverse transplant centers who entered searches into the Be The Match Registry’s TraxisÒ application were selected to participate in a new Search Monitoring process with a focus on decreasing the number of days it takes to find a matched unrelated donor and improving transplant center satisfaction. At several different time points in the search process (after initial activation of a donor or cord), updates were sent to the transplant center in the form of HLA advice from a group of immunogenetic experts along with meaningful proactive donor and case progression updates. Prior to the implementation of these enhanced services the average number of days needed for an unrelated donor search and overall transplant center satisfaction were recorded. At the end of the pilot it was found that the average number of days needed to identify a matched unrelated donor had decreased for transplant centers enrolled in the pilot and overall transplant center satisfaction values increased. Furthermore, transplant centers enrolled in the pilot showed a higher level of satisfaction than centers not enrolled. Because of the positive outcomes resulting from this process, all U.S. transplant centers will now receive these beneficial services. By providing transplant centers with proactive donor status updates, meaningful case progression details, and HLA expertise, transplant centers can make decisions on their patient’s behalf and move to transplant as quickly as possible.

Figure 1. the 3 year overall survival in the aGVHD group

531 CD62L and TCR ab Depletion of Donors in a Double Haploidentical BMT Model Leads to Improved Donor Engraftment Aman Seth 1, Chandrima Sinha 1, Bhaskar Kahali 1, Wing H. Leung 2, Lea Cunningham 1. 1 Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, MEMPHIS, TN; 2 Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN

Figure 2. the 3 year non-relapse mortality in the aGVHD group

Background: Hematopoietic stem cell transplantation (HSCT) is one of the most effective therapies for patients with relapsed and refractory acute leukemias. Only 25% of such patients have HLA identical siblings, leaving the majority of patients dependent upon volunteer matched unrelated donors (MUD). There can be long delays identifying matched unrelated donors. Haploidentical transplants are becoming popular alternatives to matched allogeneic transplantation due to rapid availability of related donors for transplant as well as any needed post-transplant cellular therapy. Historically, use of haploidentical transplantation was limited due